Compare Nokia Corp (NOK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Sana Biotechnology Inc — how do they compare? Nokia Corp trades at $10.41 (market cap $53.00B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Nokia Corp is far larger — about 46.9× Sana Biotechnology Inc's market cap, and Nokia Corp pays a 1.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NOK | SANA | |
|---|---|---|
Market Cap | $53.00B | $1.13B |
Sector | Technology | Health |
52-Week High | $16.83 | $5.92 |
52-Week Low | $4.13 | $2.68 |
Enterprise Value | $50.95B | $1.05B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.315, up 13.1% on the day, reflecting positive momentum. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, revenue was $19.89B in 2025 with a net income margin of 3.47%, while the P/E ratio of 68.07 suggests a premium valuation. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. News highlights focus on AI infrastructure growth driving demand.
The outlook is cautiously optimistic, supported by strong analyst buy consensus (59.61%) and AI-driven demand tailwinds. However, risks include competitive pressures in telecom, volatility in cash flows, and the high P/E ratio indicating stretched valuations. Investment appeal hinges on successful execution in AI and cloud segments offsetting traditional market challenges.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
